Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RENAISSANCE Study: A Phase 2a, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Next Previous
X
Search
Trial Profile

RENAISSANCE Study: A Phase 2a, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Huperzine A (Primary)
  • Indications Epilepsy; Seizures
  • Focus Adverse reactions
  • Acronyms RENAISSANCE Study
  • Sponsors Supernus Pharmaceuticals

    • Most Recent Events

    • 02 Aug 2024 According to a Supernus Pharmaceuticals media release, the Company continues to expect topline results for the full study in the second half of 2024.
    • 23 May 2024 Interim results (n=41 as of May 1, 2024) were presented in a Supernus Pharmaceuticals Media Release.
    • 09 May 2024 According to a Supernus Pharmaceuticals media release, Company will hold a webcast and conference call on Thursday, May 23, 2024 to review interim data from this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top